NCT03473925View on ClinicalTrials.gov

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions
Solid TumorsNon-small Cell Lung CancerCastration Resistant Prostate CancerMicrosatellite Stable Colorectal Cancer
Interventions
DRUG

Navarixin

Oral capsules

BIOLOGICAL

Pembrolizumab

Intravenous infusion

Trial Locations (14)

2031

Scientia Clinical Research ( Site 0021), Randwick

2148

Blacktown Hospital Western Sydney Local Health District ( Site 0024), Blacktown

3000

Peter MacCallum Cancer Centre ( Site 0023), Melbourne

13620

Seoul National University Bundang Hospital ( Site 0043), Seongnam-si

21201

University of Maryland ( Site 0008), Baltimore

27710

Duke University Medical Center ( Site 0004), Durham

34232

Florida Cancer Specialists ( Site 0003), Sarasota

48202

Henry Ford Health System ( Site 0006), Detroit

85258

Honor Health ( Site 0005), Scottsdale

6423906

Sourasky Medical Center ( Site 0012), Tel Aviv

M5G 2M9

Princess Margaret Cancer Centre ( Site 0031), Toronto

H3T 1E2

Jewish General Hospital ( Site 0032), Montreal

03080

Seoul National University Hospital ( Site 0042), Seoul

03722

Severance Hospital Yonsei University Health System ( Site 0041), Seoul

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03473925 - Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | Biotech Hunter | Biotech Hunter